Literature DB >> 9951682

Oligoclonal T cells in human cancer.

E Halapi1.   

Abstract

Many solid tumors are characterised by the infiltration of lymphocytes and their presence has been correlated with a more favourable prognosis. These tumor-infiltrating lymphocytes (TIL), have been shown to possess specific cytolytic reactivity towards autologous tumours, thus suggesting that tumour cells may express antigens capable of eliciting an immune response. Expression of such tumour-associated antigens (TAA) in combination with appropriate accessory signals would lead to the in vivo accumulation of T cells with anti-tumour specificity. Analysis of the composition of the specific T-cell receptor (TCR) of TIL could thus provide information on the nature of the antigen(s) recognised by TIL. In this review, different aspects of the presence of clonal T cells in patients with cancer are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951682     DOI: 10.1007/BF02787202

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  103 in total

1.  ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain.

Authors:  A C Chan; M Iwashima; C W Turck; A Weiss
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

2.  The presumptive CDR3 regions of both T cell receptor alpha and beta chains determine T cell specificity for myoglobin peptides.

Authors:  J S Danska; A M Livingstone; V Paragas; T Ishihara; C G Fathman
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

3.  Biased expression of individual T cell receptor V gene segments in CD4+ and CD8+ human peripheral blood T lymphocytes.

Authors:  J Grunewald; C H Janson; H Wigzell
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

4.  Short related sequences in the cytoplasmic domains of CD4 and CD8 mediate binding to the amino-terminal domain of the p56lck tyrosine protein kinase.

Authors:  A S Shaw; J Chalupny; J A Whitney; C Hammond; K E Amrein; P Kavathas; B M Sefton; J K Rose
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

5.  Genomically imposed and somatically modified human thymocyte V beta gene repertoires.

Authors:  R Baccala; D H Kono; S Walker; R S Balderas; A N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  Oligoclonal T lymphocytes infiltrating human lung cancer tissues.

Authors:  I Yoshino; T Yano; Y Yoshikai; M Murata; K Sugimachi; G Kimura; K Nomoto
Journal:  Int J Cancer       Date:  1991-03-12       Impact factor: 7.396

7.  The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

Authors:  E Weidmann; T L Whiteside; R Giorda; R B Herberman; M Trucco
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

8.  Evidence for the effects of a superantigen in rheumatoid arthritis.

Authors:  X Paliard; S G West; J A Lafferty; J R Clements; J W Kappler; P Marrack; B L Kotzin
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

9.  The genetic contribution to human T-cell receptor repertoire.

Authors:  J A Loveridge; W M Rosenberg; T B Kirkwood; J I Bell
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

10.  Increased frequency of T cell receptor V alpha 12.1 expression on CD8+ T cells: evidence that V alpha participates in shaping the peripheral T cell repertoire.

Authors:  H DerSimonian; H Band; M B Brenner
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  8 in total

Review 1.  At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

Authors:  Anthony F O Daniyan; Renier J Brentjens
Journal:  J Leukoc Biol       Date:  2016-10-27       Impact factor: 4.962

2.  Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy.

Authors:  Roman A Blaheta; Maciej Powerski; Lukasz Hudak; Eva Juengel; Dietger Jonas; Andreas von Knethen; Hans Willhelm Doerr; Jindrich Cinatl
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

3.  Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.

Authors:  Zhi-Yu Xiao; Wei Wu; Navada Eagleton; Huan-Qing Chen; Jing Shao; Hong Teng; Tian-Hao Liu; Zhi-Min Jiang; He-Rui Yao
Journal:  World J Gastroenterol       Date:  2010-01-07       Impact factor: 5.742

4.  Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer.

Authors:  H Yao; E Song; J Chen; P Hamar
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

5.  Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.

Authors:  E Song; J Chen; N Ouyang; F Su; M Wang; U Heemann
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

6.  A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma.

Authors:  Shan-Shan Jiang; Yan Tang; Yao-Jun Zhang; D-Sheng Weng; Zhong-Guo Zhou; Ke Pan; Qiu-Zhong Pan; Qi-Jing Wang; Qing Liu; Jia He; Jing-Jing Zhao; Jiang Li; Min-Shan Chen; Alfred E Chang; Qiao Li; Jian-Chuan Xia
Journal:  Oncotarget       Date:  2015-12-01

Review 7.  Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Authors:  Christine Ménétrier-Caux; Isabelle Ray-Coquard; Jean-Yves Blay; Christophe Caux
Journal:  J Immunother Cancer       Date:  2019-03-28       Impact factor: 13.751

Review 8.  Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers.

Authors:  Meng Li; Denis Kaili; Lei Shi
Journal:  World J Gastrointest Oncol       Date:  2022-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.